645 Results
Sort By:
Published on June 21, 2024
A vaccine for Parkinson’s disease could be on the horizon, according to a new study published in Nature Medicine. Vaxxinity’s immunotherapy targeting pathogenic α-synuclein aggregates has achieved its immunogenicity, safety, and tolerability goals in a phase I clinical trial in Parkinson’s patients. The vaccine, known as UB-312, was shown to…
Published on June 13, 2024
The neurotoxic side effects of anti-PD-1 immunotherapy have been a mystery, but new research has revealed a possible drug target that could help alleviate these effects. These side effects have reduced the efficacy of this revolutionary cancer treatment. Anti-PD1 immunotherapy causes neurotoxicity in mice by activating microglia, according to a…
Published on June 5, 2024
In a proof-of-concept study published in Nature Cancer, scientists have shown that their artificial intelligence tool improves the predictive likelihood of a patient responding to immune checkpoint inhibitors. Known as the Logistic Regression-Based Immunotherapy-Response Score (LORIS), the tool relies on six common data points and computes a score predicting whether…
Published on June 5, 2024
A machine learning pipeline that combines multiple omics datasets was used to derive a new transcriptomic footprint correlated with positive outcomes in patients with advanced kidney cancer who underwent immunotherapy. The approach identified the molecular characteristics of an immune signaling hub distinguished by a human leukocyte antigen (HLA) repertoire with…
Published on June 4, 2024
Researchers at University College London (UCL) and University College London Hospitals (UCLH) have discovered that an immunotherapy drug, pembrolizumab, significantly increases the number of patients who are cancer-free after surgery for bowel cancer, according to interim results from the NEOPRISM-CRC phase II clinical trial presented at the American Society of…
Published on May 29, 2024
Researchers at the University College London (UCL) and UCL Great Ormond Street Institute of Child Health have developed a novel immunotherapeutic platform technology that uses engineered T cells to attack bone cancer cells and activate other cancer-fighting immune cells to do the same. The researchers aimed to overcome different challenges…
Published on May 22, 2024
A preclinical study by Cleveland Clinic researchers reveals that the immune checkpoint protein VISTA can turn off tumor-fighting T cells during immunotherapy and resist treatment. The work using mouse models, showed that VISTA can bind to a protein called LRIG1 in T cells, which was previously only thought to promote…
Published on May 22, 2024
Researchers at Washington University School of Medicine have found in a mouse study that a strain of the gut bacteria Ruminococcus gnavus can help enhance the effectiveness of cancer immunotherapy. The research, published in Science, points to the potential of using R. gnavus as a probiotic agent to improve the…
Published on May 16, 2024
A Phase III study from The University of Texas MD Anderson Cancer Center has revealed that combining perioperative immunotherapy with chemotherapy significantly improves outcomes for patients with resectable early-stage non-small cell lung cancer (NSCLC). The research, published in the New England Journal of Medicine, demonstrates that administering nivolumab both before…
Published on April 19, 2024
In a clinical trial, researchers at the Dana-Farber Cancer Institute in Boston, MA, have demonstrated that administering the immunotherapy drug pembrolizumab after surgery can significantly improve overall survival rates for patients with a high risk of recurring kidney cancer. Published in the New England Journal of Medicine, the study’s findings…
Published on April 9, 2024
Microbes within metastatic cancer tumors could affect the success of immunotherapy, a study has found, with one bacterium in particular implicated in poor outcomes. The research in more than 4000 tumor tissue samples, involving 26 types of cancer, could guide the development of bacteria-oriented strategies to enhance cancer therapy. The…
Published on April 5, 2024
Obsidian Therapeutics this week closed an oversubscribed $160.5 million Series C financing to try and crack the immunotherapy for solid tumors problem. The financing was led by Wellington Management. Obsidian’s lead candidate, OBX-115, is a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) “armored with pharmacologically…
Published on April 3, 2024
Gilead Sciences will develop and commercialize Xilio’s Phase I tumor-activated IL-12 program. Xilio’s lead candidate, XTX301, is a tumor-activated IL-12 designed to potently stimulate anti-tumor immunity and reprogram the tumor microenvironment (TME) of poorly immunogenic “cold” tumors towards an inflamed or “hot” state and thus more sensitive to immunotherapy. IL-12…
Published on March 20, 2024
Researchers from Boston University Chobanian & Avedisian School of Medicine have discovered that the signaling molecule chemokine-like factor (CKLF) plays a key role in promoting immunosuppression and tumor aggression in neuroblastoma and potentially in other tumors with abnormal activation of the MYCN oncoprotein. “The MYCN oncoprotein drives the initiation, progression,…
Published on February 29, 2024
More people could benefit from personalized cancer immunotherapy using a newly developed discovery platform that can identify novel biomarkers and targets for treatment. The “identify-prioritize-validate” (IPV) pipeline offers a more accessible and reliable way to identify neoantigen proteins that are produced by genetic mutations in a tumor and the immune…